Presentation is loading. Please wait.

Presentation is loading. Please wait.

An introduction to EMA’s support for medicines development

Published byLeen Beckers Modified over 5 years ago

Similar presentations

Presentation on theme: "An introduction to EMA’s support for medicines development"— Presentation transcript:

1 An introduction to EMA’s support for medicines development
27 May 2019 An introduction to EMA’s support for medicines development BioCapital Europe 2019, Amsterdam 14 March 2019 Presented by Michael Berntgen Head of Product Development Scientific Support Department

2 These PowerPoint slides are copyright of the European Medicines Agency
These PowerPoint slides are copyright of the European Medicines Agency. Reproduction is permitted provided the source is acknowledged. An introduction to EMA’s support for medicines development 14 March 2019

3 EMA’s early development advice services
Innovation task force (ITF) as discussion platform for early dialogue with sponsors Scientific advice on the appropriate tests and studies in the development of a medicine, including engagement with other decision makers PRIME scheme for enhanced support of medicines targeting an unmet medical need Qualification of novel methodologies in the context of research and development Specific frameworks for paediatric development and orphan medicines SME support including briefing meetings to discuss regulatory strategies as well as certification of quality and non-clinical data for ATMPs PRIME = PRIority MEdicines; SME = micro, small and medium-sized enterprises; ATMP = Advanced therapy medicinal product An introduction to EMA’s support for medicines development 14 March 2019

4 Clinical confirmatory Clinical exploratory
27 May 2019 Clinical confirmatory Clinical exploratory Non-clinical and First in Man Authorisation Access decision Post-licensing evidence Early Research Innovation Task Force and EU-IN Scientific Advice/Protocol Assistance PRIME support ATMP certification Orphan Drug Designation Paediatric Investigation Plan Qualification of Novel Methodologies SME briefings An introduction to EMA’s support for medicines development EU-IN = EU Innovation Network 14 March 2019

5 Innovation Task Force and EU Innovation Network
27 May 2019 Innovation Task Force and EU Innovation Network Product/technology/methodology-specific Support drug development via early informal dialogue in so-called “ITF briefing meetings” on scientific, legal and regulatory issues Preparing for formal procedures Cross-development Address impact of emerging therapies and technologies on the regulatory system Identifying emerging trends that may require regulatory guidance and support Assist knowledge exchange on innovative strategies involving regulatory network Collaboration with the national innovation offices through the EU Innovation Network, addressing gaps in early regulatory support to innovation An introduction to EMA’s support for medicines development 14 March 2019

6 Scientific Advice and Protocol Assistance
Advising Applicants on the various tests and trials necessary to demonstrate the quality, safety and efficacy of medicinal products". Clarifying the scientific requirements for marketing authorisation (MA), including: Manufacturing, non-clinical and clinical trials, risk-management plans, ways to develop generics, hybrids and biosimilars, significant benefit for orphan medicines, development in children etc. Post-licencing extension of indication to different age groups / stages of the disease / different conditions, evidence generation on safety aspects etc. Prospective in nature - focusing on development strategies rather than pre-evaluation of data to support a MAA. An introduction to EMA’s support for medicines development 14 March 2019

7 Qualification of novel methodologies and biomarkers
Framework to guide the development of new more efficient ways to develop drugs, e.g. development of new endpoints for clinical trials Aim: Speed up/optimise drug development and utilisation, improve public health Examples: Methods to predict toxicity; strategies to enrich a patient population for a clinical trial Surrogate clinical endpoints Patient and caregiver reported outcomes, patient registries An introduction to EMA’s support for medicines development 14 March 2019

8 PRIME scheme Reinforce scientific and regulatory advice ?
27 May 2019 PRIME scheme To foster the development of medicines with major public health interest ? ! Reinforce scientific and regulatory advice Foster and facilitate early interaction Raise awareness of requirements earlier in development Optimise development for robust data generation Focus efficient development Promote generation of robust and high quality data Enable accelerated assessment Promote generation of high quality data Facilitated by knowledge gained throughout development An introduction to EMA’s support for medicines development 14 March 2019

9 Special populations: Paediatrics and orphan diseases
Paediatric Investigation Pan Basis for development and authorisation of a medicine for all paediatric population subsets. Includes details of the timing and the measures proposed, to demonstrate Quality, Safety and Efficacy Binding on company  compliance check (as a basis for the incentives e.g. SPC extension) Orphan Designation Orphan designation - related incentives (such as development support, fee reduction, market exclusivity) Scientific advice for orphan medicines is called protocol assistance, also covering questions on studies needed to demonstrate the significant benefit of the medicine An introduction to EMA’s support for medicines development SPC = Supplementary Protection Certificate 14 March 2019

10 Optimised development plan  Improved access for patients
Evidence planning also for later access decision: Parallel scientific advice with HTA bodies Facilitation of an optimal and robust evidence generation for different stakeholders bringing benefits for patient access and public health Increased opportunities for mutual understanding and problem-solving ability between EMA and HTA bodies through a more structured interaction Optimised development plan  Improved access for patients EUnetHTA = European network for health technology assessment; HTAs = Health Technology Assessment bodies An introduction to EMA’s support for medicines development 14 March 2019

11 Providing specific support for SMEs
27 May 2019 Providing specific support for SMEs SME Briefing meetings to discuss regulatory strategy and navigate the range of procedures and incentives available Multidisciplinary group (scientific advice, paediatrics, orphans, regulatory affairs, etc); open to medicinal products for human and veterinary use; fee reductions for EMA procedures Certification of quality and non-clinical data for ATMPs Scientific evaluation of quality data and, when available, non-clinical data that SMEs have generated at any stage of the ATMP development process. Aims to identify any potential issues to be addressed early on, prior to the submission of MAA An introduction to EMA’s support for medicines development 14 March 2019

12 Take home messages EMA is open to discuss scientific, regulatory and technical aspects of medicines developments Different platforms depending on scope, timing and contributors to such engagement on R&D activities Multiple engagement opportunities to support developers and investors in their decision making to mitigate the risk of failures Overview: EMA Supporting medicine developers An introduction to EMA’s support for medicines development 14 March 2019

13 Thank you for your attention
27 May 2019 Thank you for your attention Further information: List of available guidance and opportunities for interaction European Medicines Agency 30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website Follow us on @EMA_News

Download ppt "An introduction to EMA’s support for medicines development"

Similar presentations

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Susan Boynton, VP, Global Regulatory Affairs, Shire

Susan Boynton, VP, Global Regulatory Affairs, Shire
The Paediatric Regulation

The Paediatric Regulation
An agency of the European Union The SME Office at the European Medicines Agency Constantinos Ziogas SME Office, Stakeholder & Communication Division, European.

An agency of the European Union The SME Office at the European Medicines Agency Constantinos Ziogas SME Office, Stakeholder & Communication Division, European.
Health Line of Business Revised Health Domains January 26, 2005 Outcomes / Domains have been revised.

Health Line of Business Revised Health Domains January 26, 2005 Outcomes / Domains have been revised.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Collaboration between FDA and EMA

Collaboration between FDA and EMA
Urban-Nexus – Integrated Urban Management David Ludlow and Michael Buser UWE Sofia 17-18 November 2011.

Urban-Nexus – Integrated Urban Management David Ludlow and Michael Buser UWE Sofia November 2011.
Accessibility Planning, Training & Advisory Programme Making the connections—making it happen Putting Accessibility Planning withinreach! Derek Palmer.

Accessibility Planning, Training & Advisory Programme Making the connections—making it happen Putting Accessibility Planning withinreach! Derek Palmer.
Benefits of a strong collaboration with patient groups at national and EU level Susanna Palkonen, Director European Federation.

Benefits of a strong collaboration with patient groups at national and EU level Susanna Palkonen, Director European Federation.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.

Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.
Adaptive Licensing UK. Content What is adaptive licensing? Draft criteria for pilot candidate selection EMA Road Map 2015 and work programme 2012 UK perspective.

Adaptive Licensing UK. Content What is adaptive licensing? Draft criteria for pilot candidate selection EMA Road Map 2015 and work programme 2012 UK perspective.
1. 2 >70 300 ˜100 3 >2 000 >380 000 4 Paediatric regulation.

1. 2 > ˜100 3 >2 000 > Paediatric regulation.
Biotechnology Industry Organization (BIO) Risk Management Public Workshop Day 1 - April 9, 2003 Risk Assessment in Drug and Biological Development Joanna.

Biotechnology Industry Organization (BIO) Risk Management Public Workshop Day 1 - April 9, 2003 Risk Assessment in Drug and Biological Development Joanna.
European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Post-Authorisation Efficacy Studies (PAES)

European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Post-Authorisation Efficacy Studies (PAES)
Science is leading the revolution in targeted, personalised therapies:

Science is leading the revolution in targeted, personalised therapies:
Slide 1 Encouraging innovation: the regulators perspective Bringing the best to healthcare through partnership and innovation IPHA, 1 st December 2011.

Slide 1 Encouraging innovation: the regulators perspective Bringing the best to healthcare through partnership and innovation IPHA, 1 st December 2011.
China EU Pharmaceutical Forum

China EU Pharmaceutical Forum
Gwendolyn Ryals, Look at Me Artwork from The Creative Center Janey Shin, Director, Real World Evidence Government Affairs and Market Access CADTH Symposium.

Gwendolyn Ryals, Look at Me Artwork from The Creative Center Janey Shin, Director, Real World Evidence Government Affairs and Market Access CADTH Symposium.

Similar presentations

Ads by Google